Drug Profile
Research programme: NMDA receptor agonists - Tikvah
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Apkarian Technologies LLC; Therapade Technologies LLC
- Developer Tikvah Therapeutics
- Class
- Mechanism of Action NMDA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anxiety disorders; Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anxiety-disorders in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA
- 13 Feb 2007 Preclinical trials in Anxiety disorders in USA (PO)